Evaluate the efficacy and safety of Levetiracetam for prophylaxis and treatment of febrile seizure in children

Evaluate the efficacy and safety of Levetiracetam for prophylaxis and treatment of febrile seizure

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCC-11001874

Enrollment

Unknown

Registered

2011-12-05

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febrile seizure

Interventions

A:NA

B:starting dose with LEV 30mg/kg

Eligibility

Sex/Gender

All

Age

4 Years to 14 Years

Inclusion criteria

Inclusion criteria: Patient who with febrile seizure and under 14 years' children; and more than 2 seizures

Exclusion criteria

Exclusion criteria: 1. Subject with a known history of severe anaphylactic reaction or serious blood dyscrasias; 2. Subject has an acute or sub-acute progressive central nervous system disease.

Design outcomes

Primary

Measure	Time frame
seizure freedom;AE;EE;	—

Countries

China

Contacts

Public ContactLiping Zou

zouliping21@sina.com+86 10 66939770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026